We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

152 hedge funds and large institutions have $1.26B invested in Acorda Therapeutics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 40 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 40

26% more capital invested

Capital invested by funds: $1B → $1.26B (+$258M)

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

1% more funds holding

Funds holding: 151 → 152 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

19% less call options, than puts

Call options by funds: $6.72M | Put options by funds: $8.28M

Holders
152
Holders Change
+1
Holders Change %
+0.66%
% of All Funds
3.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
61
Reduced
40
Closed
17
Calls
$6.72M
Puts
$8.28M
Net Calls
-$1.56M
Net Calls Change
+$10.6M

Top Buyers

1
PHS
PFM Health Sciences
California
+$32.1M
2
SCM
Scopia Capital Management
New York
+$27.5M
3
Invesco
Invesco
Georgia
+$15.4M
4
BBA
Baker Bros. Advisors
New York
+$11.4M
5
Deutsche Bank
Deutsche Bank
Germany
+$9.45M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$20.3M
2
CI
Cambiar Investors
Colorado
-$11.8M
3
GTC
Ghost Tree Capital
New York
-$7.88M
4
State Street
State Street
Massachusetts
-$6.39M
5
USAA
United Services Automobile Association
Texas
-$4.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
51
Wells Fargo
California
$2.02M +$15.8K +6 +0.9%
UBS Group
52
UBS Group
Switzerland
$1.91M +$943K +358 +114%
TA
53
Teachers Advisors
New York
$1.86M -$5.27K -2 -0.3%
Morgan Stanley
54
Morgan Stanley
New York
$1.85M -$1.69M -641 -50%
MWNA
55
Marshall Wace North America
New York
$1.81M +$256K +97 +18%
Swiss National Bank
56
Swiss National Bank
Switzerland
$1.8M – – –
Citigroup
57
Citigroup
New York
$1.7M -$1.1M -418 -41%
AllianceBernstein
58
AllianceBernstein
Tennessee
$1.69M – – –
California State Teachers Retirement System (CalSTRS)
59
California State Teachers Retirement System (CalSTRS)
California
$1.64M -$166K -63 -10%
PI
60
PineBridge Investments
New York
$1.61M -$158K -60 -10%
California Public Employees Retirement System
61
California Public Employees Retirement System
California
$1.55M +$23.7K +9 +2%
Allianz Asset Management
62
Allianz Asset Management
Germany
$1.55M +$169K +64 +13%
KBC Group
63
KBC Group
Belgium
$1.51M +$927K +352 +194%
Canada Life
64
Canada Life
Manitoba, Canada
$1.46M -$119K -45 -8%
JCP
65
Jabre Capital Partners
Switzerland
$1.42M -$877K -333 -40%
VEA
66
Virtus ETF Advisers
New York
$1.42M – – –
PIM
67
Partner Investment Management
California
$1.42M +$266K +101 +25%
MCC
68
Malaga Cove Capital
California
$1.41M – – –
New York State Teachers Retirement System (NYSTRS)
69
New York State Teachers Retirement System (NYSTRS)
New York
$1.4M – – –
Comerica Bank
70
Comerica Bank
Texas
$1.34M +$7.9K +3 +0.7%
CIP
71
Convergence Investment Partners
Florida
$1.29M +$1.2M +456 New
SI
72
Scout Investments
Missouri
$1.17M – – –
New York State Common Retirement Fund
73
New York State Common Retirement Fund
New York
$1.11M – – –
CAM
74
ClariVest Asset Management
California
$1.11M – – –
AA
75
ALPS Advisors
Colorado
$1.09M +$84.3K +32 +9%
1 2
3
4 5

ACOR Hedge Fund Activity: Q3 2017 in Review

152 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2017, worth a combined $1.26B — up 26% from $1B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ACOR positions and 17 closed out — a net gain of 1 holder — while 61 added to existing stakes and 40 trimmed.

The largest buyer was PFM Health Sciences, adding an estimated $32.1M. The largest seller was Citadel Advisors, cutting an estimated $20.3M.

  • 152 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2017, up from 151 in Q2 2017.
  • Funds reported $1.26B of Acorda Therapeutics stock for Q3 2017, up 26% quarter-over-quarter.
  • 18 funds opened new Acorda Therapeutics positions in Q3 2017 and 17 closed out, a net change of +1 holder.
  • The largest Acorda Therapeutics buyer in Q3 2017 was PFM Health Sciences, an estimated $32.1M added.
  • The largest Acorda Therapeutics seller in Q3 2017 was Citadel Advisors, an estimated $20.3M sold.

Based on aggregated 13F filings for Q3 2017.